Key facts
- Pallando Therapeutics’s last known valuation is $28.7M (Jun 2025).
- It has raised $17.0M; the latest was Seed Round ($8.0M) in Jun 2025.
- Notable investors include General Catalyst, Mana Ventures, Gaingels, 8VC, Calm Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Pallando Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pallando Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pallando Therapeutics
Provider of precision targeting services intended to transform the oncology treatment landscape. The company is currently operating in stealth mode.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2023
- Employees
- 6
- Website
- pallandotx.com/
- Ownership
- Privately Held (backing)
Pallando Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pallando Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pallando Therapeutics in its N-PORT filings yet. We sweep new filings monthly.